"Designing Growth Strategies is in our DNA"
Ulcerative colitis is a type of inflammatory bowel disease (IBD) where the colon or inner lining of the stomach becomes inflamed that results in the development of ulcers, or tiny open sores which could bleed and causes abdominal discomfort. Fatigue, loss of appetite, fever, diarrhea, rectal pain, and bleeding, etc. are some of the symptoms associated with ulcerative colitis. In 2015, according to the Centers for Disease Control and Prevention (CDC), it was estimated that 1.0 to 1.3 million people globally suffered from inflammatory bowel disease.
Anti-inflammatory drugs such as 5-aminosalicylic acid and corticosteroids are used as first-line therapy in the treatment of ulcerative colitis. Based on the severity of the symptoms, immunosuppressant drugs such as cyclosporine and azathioprine and biologics such as infliximab are used to treat ulcerative colitis. In addition, in most severe cases, surgical procedures such as ileal pouch-anal anastomosis are opted to treat ulcerative colitis.
Many pharmaceutical companies along with government research institutes have been focusing on studying and developing new treatment options for ulcerative colitis. For instance; RO7049665, which is being studied by F. Hoffmann-La Roche Ltd is currently in phase-1 clinical trials study for RO7049665 in Patients with Ulcerative Colitis (UC).
To know how our report can help streamline your business, Speak to Analyst
At present, around 63% of the pipeline candidates for ulcerative colitis are in the phase-2 and phase-4 stage. Majority of the studies have been conducted by industries and by government-funded organizations.
The report on ‘Ulcerative Colitis – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Ulcerative Colitis. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Ulcerative Colitis.
The report on ‘Ulcerative Colitis – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.